Repligen Co. (NASDAQ:RGEN) Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 60.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,000 shares of the biotechnology company’s stock after selling 15,000 shares during the period. Sivik Global Healthcare LLC’s holdings in Repligen were worth $1,439,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RGEN. UMB Bank n.a. increased its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the period. First Turn Management LLC acquired a new position in Repligen in the 3rd quarter valued at approximately $13,202,000. Thrivent Financial for Lutherans increased its stake in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after buying an additional 36,773 shares during the period. Geneva Capital Management LLC increased its stake in Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after buying an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC increased its stake in Repligen by 14.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after buying an additional 35,115 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 0.1 %

Shares of NASDAQ RGEN opened at $174.07 on Thursday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a market cap of $9.75 billion, a PE ratio of -461.96, a P/E/G ratio of 4.51 and a beta of 0.97. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average of $153.24 and a two-hundred day moving average of $147.20.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter in the previous year, the company earned $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. As a group, equities analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on RGEN shares. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. HC Wainwright cut their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average target price of $184.73.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.